Plant-Based Diet CKD Feasibility Study, Changi General Hospital, Singapore
Summary
A two-year follow-up, single-center, open-label feasibility study will recruit outpatients from the Renal Medicine Clinic at Changi General Hospital, Singapore. Eligible patients with Stage 3 or 4 chronic kidney disease will be assigned to either a predominantly plant-based diet intervention (at least 50% protein from plant sources) with regular dietitian counselling, or a control group receiving standard CKD dietary advice. Six monthly assessments will measure eGFR, serum potassium, nutritional markers, and quality of life outcomes through questionnaires and food frequency records. The study aims to evaluate feasibility, safety regarding hyperkalaemia incidence, and potential benefit in terms of acidosis improvement in the Singaporean context.
“This two-year follow up, single-center, open-label, feasibility study will recruit outpatients from the Renal Medicine Clinic at Changi General Hospital.”
About this source
GovPing monitors ClinicalTrials.gov Studies for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 686 changes logged to date.
What changed
This ClinicalTrials.gov registration documents a new two-year feasibility study evaluating a predominantly plant-based diet in Singaporean patients with Stage 3 or 4 chronic kidney disease. The intervention group will receive dietitian counselling emphasising at least 50% protein from plant sources, while the control group will receive standard CKD dietary guidance. Participants will be assessed every six months for eGFR, serum potassium, nutritional markers, and quality of life. This registration does not create any regulatory obligations or compliance requirements for healthcare providers, manufacturers, or other parties. It represents an informational record of planned clinical research rather than a regulatory action or enforcement measure.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Feasibility, Safety and Efficacy of a Predominantly Plant-based Diet in an Asian Population With Chronic Kidney Disease
N/A NCT07544524 Kind: NA Apr 22, 2026
Abstract
This two-year follow up, single-center, open-label, feasibility study will recruit outpatients from the Renal Medicine Clinic at Changi General Hospital. Eligible patients with Stage 3 or 4 CKD will be assigned preferencebased to either a plant-based diet intervention (intake of at least 50% protein from plant sources) with regular dietitian counselling and follow up, or a control group receiving dietitian counselling for general CKD dietary advice without information on percentage of plant-based foods. Six monthly assessments will include estimated glomerular filtration rate (eGFR), serum potassium, nutritional markers, and other relevant biochemical parameters. Quality of life and dietary adherence will be evaluated through questionnaires and food frequency records. This study will evaluate primarily, the feasibility of a plant-based diet in the Singaporean context. Secondarily it will evaluate its safety in terms of incidence of hyperkalaemia, and benefit in terms of improvement in acidosis.
Other exploratory outcomes will include (1) preliminary efficacy of plant-based diets on CKD progression (measured by eGFR decline); (2) risk of nutritional deficiencies such as vitamin D, B12 and iron; and (3) impact on other biochemical parameters of CKD.
Conditions: Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, Diet Habit
Interventions: Predominantly Plant-Based CKD Diet, Standard CKD Diet
Mentioned entities
Parties
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.